: Preliminary Israeli study shows fourth COVID booster doesn’t stop omicron infections

Daily Trade

A second booster of COVID-19 vaccines from Pfizer and Moderna failed to prevent infections of the omicron variant, according to a preliminary study by a hospital in Israel.

The vaccines lifted antibodies “even a little bit higher than what we had after the third dose,” said Gili Regev-Yochay, director of the Infectious Diseases Unit, at Israel’s Sheba Medical Center, according a Reuters report Tuesday. “Yet, this is probably not enough for the Omicron.”

The unpublished study looked at the effect of a second Pfizer-BioNTech
PFE,
-1.06%

BNTX,
-3.44%

booster on 154 people after two weeks and a second Moderna
MRNA,
-2.59%

booster among 120 people following one week. The vaccinated group was then compared to a control group with no fourth booster. The Moderna participants had previously received three Pfizer boosters.

“We know by now that the level of antibodies needed to protect and not to got infected from Omicron is probably too high for the vaccine, even if it’s a good vaccine,” said Regev-Yochay.

Read: Moderna aims for COVID/flu booster in 2023, but Fauci and other virus experts warn of challenges to come this year

Israel began rolling out fourth COVID vaccines to those over 60 and health workers in early January to combat surging cases due to the omicron variant.

Articles You May Like

3 AI Stocks That Could Be Multibaggers in the Making: April Edition
3 Steel Stocks to Sell Now on Rising Input Costs and Interest Rate Fears
3 Nasdaq Stocks That Could Be Heading Six-Feet Under
Ignore the Drama: The Smart Investor’s Approach to Trump Media Stock
Tough Times for EV Stocks: Why QuantumScape Investors Should Steer Clear